Evidence map›Paper›PMID 37495380›Full record

ReviewNeurology2023

Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology.

Vijay K Ramanan, Melissa J Armstrong, Parichita Choudhury, Katherine A Coerver, Roy H Hamilton, Brad C Klein, David A Wolk, Scott R Wessels, Lyell K Jones, AAN Quality Committee

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 4 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. The path to treating multiple-etiology dementia: Combining vascular risk control and disease-modifying neurodegenerative therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Vijay K RamananFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.ORCID https://orcid.org/0000-0001-6591-8734
Melissa J ArmstrongFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.
Parichita ChoudhuryFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.
Katherine A CoerverFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.
Roy H HamiltonFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.
Brad C KleinFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.
David A WolkFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.
Scott R WesselsFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.ORCID https://orcid.org/0009-0004-6507-282X
Lyell K JonesFrom the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.ORCID https://orcid.org/0000-0002-5851-8705
AAN Quality Committee
Banner Sun Health Research Institute · USAbington Memorial Hospital · USUniversity of Florida · US

Funding

Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9M
Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980
6 · The paper itself

Abstract

With recent data demonstrating that lecanemab treatment can slow cognitive and functional decline in early symptomatic Alzheimer disease (AD), it is widely anticipated that this drug and potentially other monoclonal antibody infusions targeting β-amyloid protein will imminently be realistic options for some patients with AD. Given that these new antiamyloid monoclonal antibodies (mAbs) are associated with nontrivial risks and burdens of treatment that are radically different from current mainstays of AD management, effectively and equitably translating their use to real-world clinical care will require systematic and practice-specific modifications to existing workflows and infrastructure. In this Emerging Issues in Neurology article, we provide practical guidance for a wide audience of neurology clinicians on logistic adaptations and decision making around emerging antiamyloid mAbs. Specifically, we briefly summarize the rationale and available evidence supporting antiamyloid mAb use in AD to facilitate appropriate communication with patients and care partners on potential benefits. We also discuss pragmatic approaches to optimizing patient selection and treatment monitoring, with a particular focus on the value of incorporating shared decision making and multidisciplinary collaboration. In addition, we review some of the recognized limitations of current knowledge and highlight areas of future evolution to guide the development of sustainable and flexible models for treatment and follow-up. As the field enters a new era with disease-modifying treatment options for AD, it will be critical for neurology practices to prepare and continually innovate to ensure optimal outcomes for patients.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, MonoclonalHumansImmunotherapyAmyloid beta-PeptidesAntibodies, Monoclonal

Identifiers

PMID37495380
PMCPMC10663011
OpenAlexW4385268425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.